| Literature DB >> 30652050 |
Yunna Kim1,2,3, Seung-Hun Cho2,3.
Abstract
OBJECTIVES: Pharmacopuncture is a treatment that medicinal fluid including herbal extract is injected in body under qi/flavor theory and meridian theories. There are a number of studies investigating the efficacy of pharmacopuncture for cervicogenic dizziness but its usage differs in each study. This study aimed to review previous studies of pharmacopuncture treatment for cervicogenic dizziness to navigate the direction of improvement.Entities:
Keywords: acupoint injection; cervicogenic dizziness; dizziness; pharmacopuncture; review
Year: 2018 PMID: 30652050 PMCID: PMC6333191 DOI: 10.3831/KPI.2018.21.027
Source DB: PubMed Journal: J Pharmacopuncture ISSN: 2093-6966
Figure 1Flowchart of literature selection on review of pharmacopuncture for cervicogenic dizziness
Characteristics of RCTs of pharmacopuncture for cervicogenic dizziness
| First Author; pub. year | No. of participants; Age | Duration of disease | Intervention type | Injection route and acupoints | Treatment period | Type of control group | Outcome measure | Results | Adverse events |
|---|---|---|---|---|---|---|---|---|---|
| Cao, 2013 [ | 120; 18 ~ 70 | 1d ~ 10y | Angelica gigas extract, IA, qd | GB20, ST36, holographic acupoints on second metacarpal bones | 11d ~ 17d | • Tuina, qd | Symptom improvement | T > C, P < 0.05 | NR |
| Chang, 2015 [ | 116; 43.0 | 10.1m | • Anisodamine | Anisodamine: GB20 Salvia miltiorrhiza, Carthamus tinctorius: IV | 10d | • Cervical traction, qid | Symptom improvement | T > C, P < 0.05 | NR |
| Huo, 2010 [ | 80; > 40 | NR | • Ligustrazine, IA, qd | Ligustrazine: GB20 Salvia miltiorrhiza, Dalbergia odorifera: IV | 22d | Salvia miltiorrhiza, Dalbergia odorifera, betahistine, IV, qd | Symptom improvement | T > C, P < 0.05 | NR |
| Li, 2006 [ | 74; 32 ~ 69 | 1y ~ 21y | Salvia miltiorrhiza, Dalbergia odorifera, IA qod | GB20 | 24d | AT, qd | Symptom improvement | T > C, P < 0.05 | NR |
| Liu, 2001 [ | 300; 27 ~ 58 | 1m ~ 12y | Salvia miltiorrhiza, Dalbergia odorifera, Angelica gigas extract, Panax notoginseng saponins, lidocaine, vitamin B12, IA, q3d | GB20, BL10, GV16 | 15d | AT, GV16 | Symptom improvement | T > C, P < 0.05 | NR |
| Wang, 2009 [ | 48; 18 ~ 77 | 20d ~ 6y | • Carthamus tinctorius, lidocaine, vitamin B12,tid | GV20, GB20, cervical paravertebral points | 12d | • Cervical traction, bid | Symptom improvement | T > C, P < 0.05 | NR |
| Cao, 2005 [ | 35; 47.9 | 1d ~ 15y | Anisodamine, lidocaine, IA, qd | GB20 | 7d | Salvia miltiorrhiza, Dalbergia odorifera, IV, qd | (1) Symptom improvement | (1) T > C, P < 0.05 | NR |
| Weng, 2006 [ | 112; > 45 | 3m~10y | • Gastrodin, IA, q3d | GB20 | 9d | Salvia miltiorrhiza, IV, qd | (1) Symptom improvement | (1) T > C, P < 0.05 | NR |
| Zou, 2007 [ | 73; 35 | 1m~6y | Salvia miltiorrhiza, qod | GB20, BL10 | 20d | Salvia medicine, IV | Symptom improvement | ||
| Ju, 2011 [ | 80; 57.5 | 11.7d | Lidocaine, vitamin B12,vitaminB1,dexamethaso ne,IA,qod | ST10, GB20, GV14, and cervical paravertebral point | 10d | • Aspirin, po | Symptom improvement | T > C, P < 0.05 | NR |
| Yang, [ | 78; NR | NR | Angelica gigas extract, Ligusticum striatum extract and Carthamus tinctorius extract, IA, qd | GB20, cervical paravertebral points, GV16 | 14d | Salvia miltiorrhiza, Dalbergia odorifera, IV, qd | Symptom improvement and change of TCD flow velocity | T > C, P < 0.05 | NR |
| Sun, 2001 [ | 242; 26 ~ 77 | 1d ~ 14y | Salvia miltiorrhiza, Dalbergia odorifera, IA qd | GV20, CV04, Jingyun acupoint, additional acupoints according to pattern differentiation | 22d | • Salvia miltiorrhiza, Dalbergia odorifera, IV, qd | Symptom improvement | T > C, P < 0.01 | NR |
| Yang, 2006 [ | 68; 29 ~ 72 | 12d ~ 7m | Salvia miltiorrhiza, Dalbergia odorifera, IA, qod | GB20, cervical paravertebral points | 27d | • Salvia miltiorrhiza, Dalbergia odorifera, IV, qd | Symptom improvement | T > C, P < 0.05 | NR |
| Wang, 2003 [ | 48; 28 ~ 67 | 3d ~ 5y | Salvia miltiorrhiza, Dalbergia odorifera, Angelica gigas extract, lidocaine, vitamin B12, IA, qd | GB20, cervical paravertebral points | 25d | • Salvia miltiorrhiza, Dalbergia odorifera, IV, qd | Symptom improvement | T > C, P < 0.05 | NR |
| Tang, 2011 [ | 60; 43 ~ 69 | NR | • Gastrodin | cervical paravertebral points | 10d | Gastrodin, IV, qd | Scoring for dizziness | T > C, P < 0.05 | NR |
| Wang, 2008 [ | 68; 42.0 | 3.2y | • Salvia miltiorrhiza, Dalbergia odorifera, IA, qd | GB20, BL10, cervical paravertebral points | 22d | • Physical therapy, cervical traction, manipulation, qd | Symptom improvement | T > C, P < 0.05 | NR |
| Xiao, 2016 [ | 114; 49.8 | 2m ~ 14y | • Gastrodin, IV, qd | IV | 20d | • Group1: AT, qd | Scoring for symptoms and function rehabilitation of cervical vertigo | • Group1: T > C, P > 0.05 | NR |
| Tan, 2013 [ | 70; 43.2 | 5d ~ 8y | Panax notoginseng saponins, IV, qd | IV | 14d | AT, qd | Symptom improvement | T < C, P < 0.05 | NR |
| Long, 2004 [ | 92; 36 ~ 70 | 2m ~ 10y | • Panax notoginseng saponins, Angelica gigas extract, Carthamus tinctorius extract, IA,qod | GB20 | 30d | • Salvia miltiorrhiza, IV, qd | (1) Symptom improvement | (1) T > C, P < 0.05 | NR |
| Zhang, 2011 [ | 75; 30 ~ 78 | 2h ~ 20y | Salvia miltiorrhiza, Dalbergia odorifera, IV, qd | IV | 10d | AT, qd~bid | Symptom improvement | T < C, P < 0.01 | NR |
| Zhu, 2012 [ | 120; 37 ~ 74 | NR | Ginkgo biloba, IV, qd | IV | 28d | AT, qd | (1) Dizziness symptom score | (1) T < C, P < 0.05 | NR |
| Li, 2006 [ | 108; 50 ~ 75 | 6m ~ 12y | Puerarin, qd | IV | 15d | AT, qd | Symptom improvement | P < 0.01 | NR |
| Li, 1998 [ | 140; 38 ~ 67 | 12d ~ 5y | • Scopolamine, vitamin B6, IA, qd | cervical paravertebral points | 10d | • Herbal medicine | Symptom improvement | T > C, P < 0.05 | NR |
| Jin, 2014 [ | 82; 37 ~ 74 | NR | • Ligustrazine, IV, qd | IV | 14d | • Cinepazide maleate, IV, qd | (1) Remission time of dizziness, tinnitus and balance disorder | (1) T < C, P < 0.05 | NR |
| Yi, 2012 [ | 98; 35 ~ 74 | NR | Ligustrazine, IV, qd | IV | 14d | Cinepazide maleate, IV, qd | Symptom improvement and change of TCD flow velocity | T < C, P < 0. 05 | NR |
| He, 2013 [ | 128; 57 ~ 78 | NR | Ligustrazine, IV, qd | IV | NR | Cinepazide maleate, IV, qd | Symptom improvement | T < C, P < 0.05 | NR |
| Yang, 2015 [ | 80; 25 ~ 72 | 5m ~ 13y | • Angelica gigas extract, Ligusticum striatum extract and Carthamus tinctorius extract, IA, qod | Ashi points, cervical paravertebral points, ST36, GB20 and BL23 | 21d | AT, qod | Symptom improvement | T > C, P < 0.05 | NR |
The values are presented as range or average.
Abbreviations: publication, pub.; number, no.; control group, C; Treatment group, T; day, d; month, m; year, y;everyday, qd; every other day, qod; every third day, q3d; twice a day, bid; three times a day, tid; four times a day, qid; acupuncture, AT; systolic velocity, Vs; diastolic velocity, Vd; vertebral artery, VA; basilar artery, BA; intra-acupoint, IA; intravenously, IV; not reported, NR;